Subscribe
vlasov-volodymyr-shutterstock-com
Vlasov Volodymyr / Shutterstock.com
21 July 2016Americas

Gilead Sciences wins Sovaldi domain dispute

Gilead Sciences has successfully transferred a domain name that included the term ‘Sovaldi’, one of the drug maker’s products.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Gilead wins second Sovaldi domain dispute
1 August 2016   The Alternative Dispute Resolution Forum has ruled in a case between Gilead Sciences and a company called PublicDomainRegistry.com, in another battle centred on Gilead’s hepatitis C drug Sovaldi.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024

More on this story

Big Pharma
Gilead wins second Sovaldi domain dispute
1 August 2016   The Alternative Dispute Resolution Forum has ruled in a case between Gilead Sciences and a company called PublicDomainRegistry.com, in another battle centred on Gilead’s hepatitis C drug Sovaldi.

More on this story

Big Pharma
Gilead wins second Sovaldi domain dispute
1 August 2016   The Alternative Dispute Resolution Forum has ruled in a case between Gilead Sciences and a company called PublicDomainRegistry.com, in another battle centred on Gilead’s hepatitis C drug Sovaldi.

More features

GSK: ‘Whoever moves first has UPC advantage’
Pfizer and BioNTech win UK COVID-19 dispute
Roche to outside counsel: ‘Law firms must adapt to the modern world’
Astellas defends blockbuster cancer treatment patent
Regeneron denied safe harbour defence in COVID-19 drug dispute
How to navigate patent term adjustment in China
Moderna wins reprieve in COVID-19 vaccine dispute
Boehringer sues Indian manufacturer over diabetes drug generic